尿白细胞介素-9与肿瘤坏死因子-α预测急性间质性肾炎预后
本研究在51例经活检证实的急性间质性肾炎患者中,评估尿IL-9和TNF-α与6个月后eGFR的关联。结果显示,尿IL-9仅在未使用糖皮质激素的患者中与较低的6个月eGFR相关;而在尿IL-9高于中位数(>0.66 ng/g)的患者中,使用糖皮质激素与较高的6个月eGFR相关。
要点
- 尿IL-9仅在未用激素的AIN患者中与6个月eGFR降低相关。
- 尿IL-9高于中位数时,激素使用与6个月eGFR升高相关。
- 间质纤维化越重,6个月eGFR越低;间质浸润越重,eGFR越高。
核心结论
- 尿IL-9仅在未接受糖皮质激素治疗的患者中与较低的6个月eGFR相关。
- 在尿IL-9高于中位数的患者中,糖皮质激素使用与较高的6个月eGFR相关。
研究设计与样本
- 队列研究,纳入55例经活检证实的急性间质性肾炎患者,其中51例(93%)有完整数据。
- 检测组织学特征和尿生物标志物(IL-9、TNF-α)与诊断后6个月eGFR的关联,并校正基线eGFR和蛋白尿。
主要发现
- 51例患者诊断前和6个月后eGFR中位数(四分位距)分别为41(27-69)和28(13-47)mL/min/1.73 m2。
- 间质纤维化程度越高,6个月eGFR越低;肾小管间质浸润程度越高,6个月eGFR越高。
- 在未使用糖皮质激素的患者中,尿IL-9每翻倍,6个月eGFR变化为-6.0(-9.4至-2.6)mL/min/1.73 m2。
- 仅在尿IL-9高于中位数(>0.66 ng/g)的患者中,糖皮质激素使用与6个月eGFR升高20.9(0.2至41.6)mL/min/1.73 m2相关。
临床怎么用
- 尿IL-9可能用于识别可能从糖皮质激素治疗中获益的AIN患者。
- 该发现为IL-9指导的免疫抑制治疗临床试验提供了框架。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously demonstrated that urine interleukin (IL)-9 and tumor necrosis factor (TNF)-α can distinguish acute interstitial nephritis (AIN) from other causes of acute kidney injury. Here we evaluated the role of these biomarkers to prognosticate kidney function in patients with AIN. METHODS: In a cohort of participants with biopsy-proven, adjudicated AIN, we tested the association of histological features and urine biomarkers (IL-9 and TNF-α) with estimated glomerular filtration rate measured 6 months after diagnosis (6 m-eGFR) controlling for eGFR before AIN and albuminuria. We also evaluated subgroups in whom corticosteroid use was associated with 6 m-eGFR. RESULTS: In the 51 (93%) of the 55 participants with complete data, median (interquartile range) eGFR before and 6 m after AIN were 41 (27-69) and 28 (13-47) mL/min/1.73 m2, respectively. Patients with higher severity of interstitial fibrosis had lower 6 m-eGFR, whereas those with higher tubulointerstitial infiltrate had higher 6 m-eGFR. IL-9 levels were associated with lower 6 m-eGFR only in the subset of patients who did not receive corticosteroids [6m-eGFR per doubling of IL-9, -6.0 (-9.4 to -2.6) mL/min/1.73 m2]. Corticosteroid use was associated with higher 6 m-eGFR [20.9 (0.2, 41.6) mL/min/1.73 m2] only in those with urine IL-9 above the median (>0.66 ng/g) but not in others. CONCLUSIONS: Urine IL-9 was associated with lower 6 m-eGFR only in participants not treated with corticosteroids. Corticosteroid use was associated with higher 6 m-eGFR in those with high urine IL-9. These findings provide a framework for IL-9-guided clinical trials to test efficacy of immunosuppressive therapy in patients with AIN.
引用
- Moledina DG, Wilson FP, Kukova L, et al. Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis. Nephrol Dial Transplant. 2021. PMID: 33125471. doi:10.1093/ndt/gfaa169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。